Regentis Biomaterials Ltd Financials

RGNT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Regentis Biomaterials Ltd (RGNT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Regentis Biomaterials Ltd passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.10x

For every $1 of reported earnings, Regentis Biomaterials Ltd generates $0.10 in operating cash flow (-$1.4M OCF vs -$13.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-88.2x

Regentis Biomaterials Ltd earns $-88.2 in operating income for every $1 of interest expense (-$7.0M vs $79K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$13.6M

YoY-384.3%

Regentis Biomaterials Ltd reported -$13.6M in net income in fiscal year 2025. This represents a decrease of 384.3% from the prior year.

EPS (Diluted)

$-24.16

Regentis Biomaterials Ltd earned $-24.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1504.7% from the prior year.

Cash & Debt

$7.4M

Regentis Biomaterials Ltd held $7.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Regentis Biomaterials Ltd had 5M shares outstanding in fiscal year 2025. This represents an increase of 3093.2% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

RGNT Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	$6.6M+832.2%	$712K-36.7%	$1.1M
Operating Income	-$7.0M-847.6%	$932K+148.3%	-$1.9M
Interest Expense	$79K+690.0%	$10K	N/A
Income Tax	N/A	N/A	N/A
Net Income	-$13.6M-384.3%	$4.8M+216.2%	-$4.1M
EPS (Diluted)	$-24.16	$1.72+107.1%	$-24.09

Metric	Q4'25	Q4'24
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

RGNT Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$7.6M+1480.5%	$482K	N/A
Current Assets	N/A	N/A	N/A
Cash & Equivalents	$7.4M	N/A	N/A
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$2.9M-93.1%	$41.6M	N/A
Current Liabilities	$2.9M-55.7%	$6.5M	N/A
Long-Term Debt	N/A	N/A	N/A
Total Equity	$4.7M+111.5%	-$41.1M+10.5%	-$45.9M
Retained Earnings	-$55.8M-32.4%	-$42.1M	N/A

Metric	Q4'25	Q4'24
Total Assets	$7.6M+1480.5%	$482K
Current Assets	N/A	N/A
Cash & Equivalents	$7.4M	N/A
Inventory	N/A	N/A
Accounts Receivable	N/A	N/A
Goodwill	N/A	N/A
Total Liabilities	$2.9M-93.1%	$41.6M
Current Liabilities	$2.9M-55.7%	$6.5M
Long-Term Debt	N/A	N/A
Total Equity	$4.7M+111.5%	-$41.1M
Retained Earnings	-$55.8M-32.4%	-$42.1M

RGNT Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$1.4M-114.5%	-$641K+47.5%	-$1.2M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A
Financing Cash Flow	$8.5M+1523.6%	$525K+61.5%	$325K
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'25	Q4'24
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

RGNT Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A
Return on Assets	-179.2%-1175.2pp	996.1%	N/A
Current Ratio	N/A	N/A	N/A
Debt-to-Equity	0.61+1.6	-1.01	N/A
FCF Margin	N/A	N/A	N/A

Metric	Q4'25	Q4'24
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	N/A	N/A
Debt-to-Equity	0.61+1.6	-1.01
FCF Margin	N/A	N/A

Frequently Asked Questions

Is Regentis Biomaterials Ltd profitable?

No, Regentis Biomaterials Ltd (RGNT) reported a net income of -$13.6M in fiscal year 2025.

What is Regentis Biomaterials Ltd's earnings per share (EPS)?

Regentis Biomaterials Ltd (RGNT) reported diluted earnings per share of $-24.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Regentis Biomaterials Ltd's operating cash flow?

Regentis Biomaterials Ltd (RGNT) generated -$1.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Regentis Biomaterials Ltd's total assets?

Regentis Biomaterials Ltd (RGNT) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Regentis Biomaterials Ltd have outstanding?

Regentis Biomaterials Ltd (RGNT) had 5M shares outstanding as of fiscal year 2025.

What is Regentis Biomaterials Ltd's debt-to-equity ratio?

Regentis Biomaterials Ltd (RGNT) had a debt-to-equity ratio of 0.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Regentis Biomaterials Ltd's return on assets (ROA)?

Regentis Biomaterials Ltd (RGNT) had a return on assets of -179.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Regentis Biomaterials Ltd's cash runway?

Based on fiscal year 2025 data, Regentis Biomaterials Ltd (RGNT) had $7.4M in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 64 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Regentis Biomaterials Ltd's Piotroski F-Score?

Regentis Biomaterials Ltd (RGNT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Regentis Biomaterials Ltd's earnings high quality?

Regentis Biomaterials Ltd (RGNT) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Regentis Biomaterials Ltd cover its interest payments?

Regentis Biomaterials Ltd (RGNT) has an interest coverage ratio of -88.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.